ACHL — Achilles Therapeutics Share Price
Last trade - 00:00- $48.70m
- -$37.35m
- 20
- 48
- 44
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 0.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.12% | ||
| Return on Equity | -52.12% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Achilles Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company has been developing artificial intelligence (AI)-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has used DNA sequencing data from each patient, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- November 18th, 2020
- Public Since
- March 31st, 2021
- No. of Employees
- 204
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 41,100,040
- Address
- 245 Hammersmith Road, Gunnels Wood Road, LONDON, W6 8PW
- Web
- https://www.achillestx.com/
- Phone
- +44 2081544600
- Auditors
- KPMG LLP
Latest News for ACHL
Upcoming Events for ACHL
Q4 2024 Achilles Therapeutics PLC Earnings Release
Q1 2025 Achilles Therapeutics PLC Earnings Release
Similar to ACHL
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 12:03 UTC, shares in Achilles Therapeutics are trading at $1.19. This share price information is delayed by 15 minutes.
Shares in Achilles Therapeutics last closed at $1.19 and the price had moved by +30.46% over the past 365 days. In terms of relative price strength the Achilles Therapeutics share price has outperformed the S&P500 Index by +7.11% over the past year.
The overall consensus recommendation for Achilles Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAchilles Therapeutics does not currently pay a dividend.
Achilles Therapeutics does not currently pay a dividend.
Achilles Therapeutics does not currently pay a dividend.
To buy shares in Achilles Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.19, shares in Achilles Therapeutics had a market capitalisation of $48.70m.
Here are the trading details for Achilles Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ACHL
Based on an overall assessment of its quality, value and momentum Achilles Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Achilles Therapeutics is $6.00. That is 406.33% above the last closing price of $1.19.
Analysts covering Achilles Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.18 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Achilles Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +32.7%.
As of the last closing price of $1.19, shares in Achilles Therapeutics were trading +29.32% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Achilles Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Achilles Therapeutics' directors